跳到正文
原文
The Lancet 柳叶刀· Brian M Slomovitz, Jianqing Zhu, Rutie Yin, Floor Backes, Mariusz Bidziński, Lucy Gilbert, Lyndsay J Willmott, Kosei Hasegawa, Jae-Weon Kim, Judith R Kroep, Ignacio Romero, Murat Gultekin, Peng-Hui Wang, Sally Baron-Hay, Jaroslav Klát, Ora Rosengarten, Maggie Polignano, Marcela Berrios, Karen Cadoo, Heini Lassus, Beata Maćkowiak-Matejczyk, Domenica Lorusso, Anna K L Reyners, Elizabeth R Burton, Vicky Makker, Lili Yao, Robin Meng, Robert Orlowski, Sandro Pignata·· 25 天前AI 评分50

派姆单抗一线治疗错配修复缺陷晚期或复发性子宫内膜癌的中期分析

[Articles] First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial

AI 导读

派姆单抗一线治疗在无进展生存期和治疗相关不良事件频率方面优于卡铂联合紫杉醇,但未与当前标准免疫治疗加化疗进行比较。

来源:The Lancet 柳叶刀 · thelancet.com